Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation

SIMPLE SUMMARY: Upfront genetics/cytogenetics and minimal measurable disease (MRD) are becoming relevant biomarkers in the process of post-remission transplant allocation in AML. However, until recently the transplantation choice relied on the availability of a fully matched familiar donor, whereas...

Descripción completa

Detalles Bibliográficos
Autores principales: Buccisano, Francesco, Palmieri, Raffaele, Piciocchi, Alfonso, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Soddu, Stefano, Cerretti, Raffaella, De Angelis, Gottardo, Mariotti, Benedetta, Irno Consalvo, Maria Antonietta, Conti, Consuelo, Fraboni, Daniela, Divona, Mariadomenica, Ottone, Tiziana, Lavorgna, Serena, Panetta, Paola, Voso, Maria Teresa, Arcese, William, Venditti, Adriano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959451/
https://www.ncbi.nlm.nih.gov/pubmed/33802502
http://dx.doi.org/10.3390/cancers13051083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959451/
https://www.ncbi.nlm.nih.gov/pubmed/33802502
http://dx.doi.org/10.3390/cancers13051083

Ejemplares similares